Moneycontrol
you are here: HomeNewsBusiness
Oct 10, 2017 03:12 PM IST

Lupin gains 3% on USFDA approval for hypertension drug

The Nadolol tablets is a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Lupin rose 3 percent intraday Tuesday on the back of USFDA approval for Nadolol tablets.

The company has received final approval for Nadolol Tablets USP 20 mg, 40 mg and 80 mg from the United States Food and Drug Administration (USFDA).

The Nadolol tablets is a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg.

The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.

According to IMS MAT June 2017 data, Nadolol tablets USP had annual sales of approximately USD 109.8 million in the US.

The company has launched Hydrocodone Bitartrate and Acetaminophen tablets USP, 5mg/325 mg, 7.5 mg / 325 mg and 10 mg / 325 mg having received an approval from the USFDA earlier.

At 15:10 hrs Lupin was quoting at Rs 1,059.50, up Rs 19.70, or 1.89 percent on the BSE.

Posted by Rakesh Patil
Sections
Follow us on
Available On